U.S. Generic Exclusivity Process To Go Public?
This article was originally published in PharmAsia News
Executive Summary
The U.S. FDA wants to know whether its 180-day generic exclusivity process should be revealed up front; the question will be one of many on ANDA reviews to be considered at a September public hearing.